Gilead Sciences
GILD
1,538 hedge funds and large institutions have $61.8B invested in Gilead Sciences in 2020 Q3 according to their latest regulatory filings, with 111 funds opening new positions, 609 increasing their positions, 640 reducing their positions, and 180 closing their positions.
5% less repeat investments, than reductions
Existing positions increased: 609 | Existing positions reduced: 640
1.2% less ownership
Funds ownership: 79.28% → 78.09% (-1.2%)
5% less funds holding
Funds holding: 1,626 → 1,538 (-88)
19% less capital invested
Capital invested by funds: $76.4B → $61.8B (-$14.6B)
20% less call options, than puts
Call options by funds: $1.47B | Put options by funds: $1.85B
31% less funds holding in top 10
Funds holding in top 10: 39 → 27 (-12)
38% less first-time investments, than exits
New positions opened: 111 | Existing positions closed: 180
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$204M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$199M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$172M |
| 4 |
BlackRock
New York
|
+$135M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$116M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$597M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$572M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$339M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$289M |
| 5 |
Goldman Sachs
New York
|
-$270M |
GILD Hedge Fund Activity: Q3 2020 in Review
1,538 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2020, worth a combined $61.8B — down 19% from $76.4B a quarter earlier.
Sellers outnumbered buyers: 180 funds closed out of GILD and 111 opened new positions — a net loss of 69 holders — while 640 trimmed existing stakes and 609 added.
The largest buyer was Federated Hermes, adding an estimated $204M. The largest seller was Capital International Investors, cutting an estimated $597M.
- 1,538 institutional investors held Gilead Sciences (GILD) as of Q3 2020, down from 1,626 in Q2 2020.
- Funds reported $61.8B of Gilead Sciences stock for Q3 2020, down 19% quarter-over-quarter.
- 111 funds opened new Gilead Sciences positions in Q3 2020 and 180 closed out, a net change of -69 holders.
- The largest Gilead Sciences buyer in Q3 2020 was Federated Hermes, an estimated $204M added.
- The largest Gilead Sciences seller in Q3 2020 was Capital International Investors, an estimated $597M sold.
Based on aggregated 13F filings for Q3 2020.